No Data
No Data
Express News | Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
BMO Capital Maintains Precision BioSciences(DTIL.US) With Buy Rating, Maintains Target Price $34
Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate
Express News | HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target
Precision BioSciences Analyst Ratings
Positive Outlook for Precision BioSciences: Promising Gene-Editing Therapy for Hepatitis B and Strong Financial Position